TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Sunday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 0.6 %

Shares of NASDAQ TXMD opened at $1.71 on Friday. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $3.25. The business has a 50 day simple moving average of $1.76 and a 200-day simple moving average of $1.95.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Institutional Trading of TherapeuticsMD

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Clearline Capital LP boosted its position in TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after purchasing an additional 101,282 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of TherapeuticsMD during the fourth quarter worth about $612,000. Finally, Prosperity Consulting Group LLC bought a new position in shares of TherapeuticsMD during the first quarter worth about $56,000. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.